Redox Pharmaceutical Corporation announced the granting of a new United States patent on the use of CTC-96 (Doxovir™) for the Treatment of Psoriasis.

Redox Pharmaceutical Corporation has successfully completed Phase IB and Phase II Clinical Trials for Herpes Labialis (cold sores).

Originally created at the Technion-Israel Institute of Technology, Doxovir™ has been developed by Redox for a variety of medical applications in research in its own laboratory and in collaboration with scientists at

• Baylor College of Medicine
• Beckman Institute at California Institute of Technology
• Columbia University
• Cornell University Weill College of Medicine
• Hadassah Medical School, Jerusalem
• Harvard University
• Mount Sinai School of Medicine
• Penn State University College of Medicine
• Public Health Research Institute of New York
• Rappaport School of Medicine at Technion
• Rush Presbyterian Medical Center in Chicago
• SUNY Stony Brook
• Technion-Israel Institute of Technology
• Tel Aviv University
• University of Alabama
• University of Cincinnati
• University of Rochester Medical School
• University of Utah School of Medicine
• Wayne State University